Arch Bio

Arch Biopartners is a clinical-stage biotechnology company focused on developing new drug candidates to prevent and treat inflammation-related organ damage. The company's lead program, LSALT peptide (also known as Metablok), targets Dipeptidase-1 (DPEP1) to inhibit the recruitment of neutrophils into various organs, including the kidneys, lungs, and liver. This mechanism is designed to prevent acute organ injury caused by sepsis, cardiac surgery, or viral infections like COVID-19. Arch Biopartners is currently advancing LSALT through Phase 2 clinical trials for the prevention of acute kidney injury. The company also maintains a pipeline of other technologies targeting brain tumors and bacterial infections.